Linked Data API

Show Search Form

Search Results

1717095
registered interest false more like this
date less than 2024-05-10more like thismore than 2024-05-10
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
hansard heading Ritlecitinib: Shropshire more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, when she expects Litfulo to be made available to NHS patients in (a) Shropshire, (b) Telford and (c) Wrekin. more like this
tabling member constituency The Wrekin more like this
tabling member printed
Mark Pritchard more like this
uin 25645 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-14more like thismore than 2024-05-14
answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new licensed medicines should be routinely funded by the National Health Service, based on an assessment of their costs and benefits.</p><p>On 27 March 2024, NICE published final technology appraisal guidance recommending ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years old and over. The NHS in England is legally required to fund medicines recommended by NICE within three months of the publication of its final guidance.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-05-14T16:53:44.207Zmore like thismore than 2024-05-14T16:53:44.207Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
1576
label Biography information for Mark Pritchard more like this